Sec Form 13G Filing - Rosalind Advisors Inc. filing for Cellectar Biosciences, Inc. (CLRB) - 2025-02-03

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  This percentage is calculated based upon 65,301,224.00 shares of the Issuer's common stock outstanding as of January 27, 2025, in accordance with Issuer's S1 filed on January 29, 2025, and preferred shares converted by Rosalind Master Fund L.P. However, the securities reported in rows (6), (8), and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers (as defined below), is less than the number of securities reported in rows (6), (8), and (9).Pursuant to the terms of the certificate of designations containing the terms of the Reported Preferred Stock, the Reporting Persons cannot convert the Reported Preferred Stock to the extent the Reporting Persons would beneficially own, after any such conversion, more than 9.99% of the outstanding shares of Common Stock (the Preferred Stock Blockers) and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Preferred Stock or any of the Reported Warrants due to the Blockers.(6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 502,320 shares of Common Stock issuable upon conversion of Preferred Stock6,970,425 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6)502,320 shares of Common Stock issuable upon conversion of Preferred Stock5,090,075 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 1,880,350 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G


 
Rosalind Advisors, Inc.
 
Signature:Steven Salamon
Name/Title:President
Date:02/03/2025
 
SALAMON STEVEN A J
 
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:02/03/2025
 
Aharon Gil
 
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:02/03/2025
 
Rosalind Master Fund L.P.
 
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:02/03/2025
 
Rosalind Opportunities Fund I L.P.
 
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:02/03/2025
primary_doc.xml